FibroGen Reports Third Quarter 2021 Financial Results
FibroGen reported significant growth in Q3 2021, with total revenue reaching $156 million, a substantial increase from $44 million in Q3 2020. This surge includes a $120 million milestone payment from Astellas following EU approval of roxadustat for CKD-related anemia. The net income also rose to $49.8 million or $0.54 per share. Additionally, net product revenue from roxadustat sales in China totaled $13.4 million for the quarter, contributing to overall sales of $57.8 million.
- Q3 2021 revenue increased to $156 million, up from $44 million in Q3 2020.
- Secured a $120 million milestone payment from Astellas for EU approval of roxadustat.
- Net income increased to $49.8 million, or $0.54 per share, compared to $33 million in Q3 2020.
- Received a complete response letter from the FDA regarding the New Drug Application for roxadustat.
- Roxadustat Receives EU approval for Patients with Anemia of CKD, triggering a
$120M milestone payment from Astellas - Roxadustat net product revenue in China of
$13.4 million , on a US GAAP basis. - Total roxadustat net sales in China of
$57.8 million 1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2021 and provided an update on the Company’s recent developments.
“We and our partner Astellas are excited to be making Evrenzo available to patients in Europe,” said Enrique Conterno, Chief Executive Officer, FibroGen. “In addition to continuously looking at opportunities to maximize the value of our portfolio of assets, following the complete response letter for roxadustat in the U.S., we are implementing a comprehensive plan which includes a cost reduction effort that will enable us to focus on our strategic priorities of development of pamrevlumab, roxadustat, and advancing our pipeline.”
Recent Key Events and Other Developments
Regulatory:
- The European Commission approved EVRENZO® (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD). Astellas has launched in Germany, the United Kingdom, Netherlands, and Austria.
- The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of CKD.
Clinical:
- Announced positive topline results from WHITNEY, the Company’s Phase 2 clinical study of roxadustat, for the treatment of chemotherapy-induced anemia (CIA). The results of the study will be presented at an upcoming medical meeting.
China:
- Roxadustat net transfer price from sales to the distribution entity (JDE) jointly owned by FibroGen and AstraZeneca was
$19.1 million for the third quarter. From the net transfer price, FibroGen defers a certain portion for revenue recognition purposes under US GAAP. FibroGen reported$13.4 million in roxadustat net product revenue for the quarter. - Total roxadustat net sales in China of
$57.8 million by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca, compared to$22.7 million in the third quarter of 2020.
Clinical Presentations / Publications:
- FibroGen and its partners presented 15 presentations at the American Society of Nephrology (ASN) Kidney Week 2021 Virtual Conference.
- One additional roxadustat Phase 3 manuscripts on the treatment of anemia of CKD was published in a peer-reviewed medical journal, bringing the total to 8:
- Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES) Advances in Therapy
- Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES) Advances in Therapy
Upcoming Data Milestones:
- Topline data from the Phase 3 MATTERHORN study of roxadustat in anemia of myelodysplastic syndromes (MDS) expected 2H 2022 / 1H 2023.
- Interim analysis of event free survival of Phase 3 LAPIS study of pamrevlumab in locally advanced pancreatic cancer (LAPC) expected in 2H 2022.
- Topline data from the Phase 3 LELANTOS-1 study of pamrevlumab in non-ambulatory Duchenne muscular dystrophy (DMD) expected 1H 2023.
- Topline data from the Phase 3 ZEPHYRUS-1 study of pamrevlumab in idiopathic pulmonary fibrosis (IPF) expected mid-2023.
Corporate
- Appointed Juan Graham as Chief Financial Officer.
- Implemented a plan to reduce our projected expenses by approximately
$100 million per year, for each of the next 3 years.
Financial:
- Total revenue for the third quarter of 2021 was
$156.0 million , as compared to$44.0 million for the third quarter of 2020. To highlight, current quarter revenue includes$120 million of milestone payments from Astellas related to the EU approval of roxadustat. - Net income for the third quarter of 2021 was
$49.8 million , or$0.54 net income per basic and diluted share, compared to a net income of$33.0 million , or$0.36 net income per basic and$0.35 per diluted share one year ago. - At September 30, FibroGen had
$665.0 million in cash, cash equivalents, investments, and accounts receivable. - Based on our latest forecast, we estimate our 2021 ending balance of cash, cash equivalents, investments, and accounts receivable to be in the range of
$580 -610 million.
Conference Call and Webcast Details
FibroGen will host a conference call and webcast today, Tuesday, November 9, 2021, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss financial results and provide a business update. A live audio webcast of the call may be accessed in the investor section of the Company’s website, www.fibrogen.com. To participate in the conference call by telephone, please dial 1 (877) 658-9081 (U.S. and Canada) or 1 (602) 563-8732 (international), reference the FibroGen third quarter 2021 financial results conference call, and use confirmation number 1747879. A replay of the webcast will be available shortly after the call for a period of 7 days. To access the replay, please dial 1 (855) 859-2056 (domestic) or 1 (404) 537-3406 (international), and use passcode 1747879.
About Roxadustat
Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. Roxadustat is also in clinical development for anemia of chronic kidney disease (CKD) and anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA).
Roxadustat is approved in European Union (EU) member states, including the European Economic Area (EEA) countries, as well as in Japan, China, Chile, and South Korea for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Several other licensing applications for roxadustat have been submitted by partners, Astellas and AstraZeneca to regulatory authorities across the globe, and are currently under review.
Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in territories including Japan, Europe, Turkey, Russia and the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in the U.S., China, other markets in the Americas, in Australia/New Zealand, and Southeast Asia.
About Pamrevlumab
Pamrevlumab is a first-in-class antibody developed by FibroGen that inhibits the activity of connective tissue growth factor (CTGF), an important biological mediator in fibrotic and proliferative disorders. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). For information about pamrevlumab studies currently recruiting patients, please visit www.clinicaltrials.gov.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com.
Forward-Looking Statements
This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development and commercialization of the company’s product candidates, the potential safety and efficacy profile of our product candidates, our clinical programs and regulatory events, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and our Quarterly Report on Form 10-Q for quarter ended September 30, 2021 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Condensed Consolidated Balance Sheets
(In thousands)
| September 30, 2021 | December 31, 2020 | ||||
| (Unaudited) | (1) | ||||
| Assets | |||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 274,527 | $ | 678,393 | |
| Short-term investments | 211,875 | 8,144 | |||
| Accounts receivable, net | 35,994 | 41,883 | |||
| Inventory | 29,315 | 16,530 | |||
| Prepaid expenses and other current assets | 21,688 | 10,160 | |||
| Total current assets | 573,399 | 755,110 | |||
| Restricted time deposits | 2,072 | 2,072 | |||
| Long-term investments | 142,636 | 244 | |||
| Property and equipment, net | 29,052 | 33,647 | |||
| Finance lease right-of-use assets | 771 | 29,606 | |||
| Equity method investment in unconsolidated variable interest entity | 3,421 | 2,728 | |||
| Operating lease right-of-use assets | 94,055 | 2,043 | |||
| Other assets | 5,107 | 1,390 | |||
| Total assets | $ | 850,513 | $ | 826,840 | |
| Liabilities, stockholders’ equity and non-controlling interests | |||||
| Current liabilities: | |||||
| Accounts payable | $ | 23,868 | $ | 24,789 | |
| Accrued and other liabilities | 151,346 | 118,333 | |||
| Deferred revenue | 23,256 | 6,547 | |||
| Finance lease liabilities, current | 15 | 12,330 | |||
| Operating lease liabilities, current | 10,831 | 1,188 | |||
| Total current liabilities | 209,316 | 163,187 | |||
| Product development obligations | 17,914 | 18,697 | |||
| Deferred revenue, net of current | 162,415 | 138,474 | |||
| Finance lease liabilities, non-current | 5 | 25,391 | |||
| Operating lease liabilities, non-current | 91,478 | 853 | |||
| Other long-term liabilities | 24,322 | 38,789 | |||
| Total liabilities | 505,450 | 385,391 | |||
| Total stockholders’ equity | 325,792 | 422,178 | |||
| Non-controlling interests | 19,271 | 19,271 | |||
| Total equity | 345,063 | 441,449 | |||
| Total liabilities, stockholders’ equity and non-controlling interests | $ | 850,513 | $ | 826,840 | |
(1) The condensed consolidated balance sheet amounts at December 31, 2020 are derived from audited financial statements.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||
| (Unaudited) | |||||||||||||||
| Revenue: | |||||||||||||||
| License revenue | $ | 116,434 | $ | — | $ | 116,434 | $ | — | |||||||
| Development and other revenue | 26,097 | 20,663 | 60,325 | 59,065 | |||||||||||
| Product revenue, net | 13,442 | 22,683 | 42,175 | 43,331 | |||||||||||
| Drug product revenue | — | 686 | (168 | ) | 8,924 | ||||||||||
| Total revenue | 155,973 | 44,032 | 218,766 | 111,320 | |||||||||||
| Operating costs and expenses: | |||||||||||||||
| Cost of goods sold | 3,266 | 2,207 | 9,746 | 6,253 | |||||||||||
| Research and development | 75,880 | 58,476 | 273,123 | 174,792 | |||||||||||
| Selling, general and administrative | 25,853 | (48,981 | ) | 89,186 | 64,157 | ||||||||||
| Total operating costs and expenses | 104,999 | 11,702 | 372,055 | 245,202 | |||||||||||
| Income (loss) from operations | 50,974 | 32,330 | (153,289 | ) | (133,882 | ) | |||||||||
| Interest and other, net: | |||||||||||||||
| Interest expense | (109 | ) | (580 | ) | (965 | ) | (1,864 | ) | |||||||
| Interest income and other income (expenses), net | (1,303 | ) | 1,482 | (2,120 | ) | 5,292 | |||||||||
| Total interest and other, net | (1,412 | ) | 902 | (3,085 | ) | 3,428 | |||||||||
| Income (loss) before income taxes | 49,562 | 33,232 | (156,374 | ) | (130,454 | ) | |||||||||
| Provision for income taxes | 106 | 215 | 235 | 190 | |||||||||||
| Investment income (loss) in unconsolidated variable interest entity | 342 | (13 | ) | 664 | (13 | ) | |||||||||
| Net income (loss) | $ | 49,798 | $ | 33,004 | $ | (155,945 | ) | $ | (130,657 | ) | |||||
| Net income (loss) per share | |||||||||||||||
| Basic | $ | 0.54 | $ | 0.36 | $ | (1.69 | ) | $ | (1.46 | ) | |||||
| Diluted | $ | 0.54 | $ | 0.35 | $ | (1.69 | ) | $ | (1.46 | ) | |||||
| Weighted average number of common shares used to calculate net income (loss) per share: | |||||||||||||||
| Basic | 92,644 | 90,558 | 92,206 | 89,414 | |||||||||||
| Diluted | 92,808 | 93,678 | 92,206 | 89,414 | |||||||||||
Contacts:
FibroGen, Inc.
Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
415.978.1434
mtung@fibrogen.com
Media:
Meichiel Keenan
Associate Director, Public Affairs
mkeenan@fibrogen.com
____________________
1 Total roxadustat net sales in China includes sales made by the distribution entity as well as FibroGen China’s direct sales, each to its own distributors. The distribution entity jointly owned by AstraZeneca and FibroGen is not consolidated into FibroGen’s financial statements.
FAQ
What are FibroGen's Q3 2021 financial results?
What milestone payment did FibroGen receive in November 2021?
How much net product revenue did FibroGen report from roxadustat sales in China?
What was FibroGen's net income per share in Q3 2021?
What was the total net sales figure for roxadustat in China?
